Similar to our findings, the TCGA analysis utilizing the dominant focus to classify patients also found that 46% of patients with primary prostate adenocarcinoma undergoing RP can be classified as ERG fusion gene subtype (2). This evidence concerns the gene ERG and prostate adenocarcinoma.